Glaxosmithkline Pharmaceuticals Ltd Quarterly Results

Gross Sales

805.17

974.37

949.42

1,010.77

814.65

Excise Duty

0

0

0

0

0

Net Sales

805.17

974.37

949.42

1,010.77

814.65

Other Operating Income

0

0

0

0

0

Other Income

43.72

40.68

35.07

39.23

35.64

Total Income

848.89

1,015.05

984.49

1,050

850.29

Total Expenditure

553.97

641.18

657.5

689.06

584.11

PBIDT

294.92

373.87

326.99

360.94

266.18

Interest

0.42

0.58

0.09

0.27

0.37

PBDT

294.5

373.29

326.9

360.67

265.81

Depreciation

15.52

14.72

18.8

16.86

16.41

Minority Interest Before NP

0

0

0

0

0

Tax

73.95

90.15

73.49

98.76

63.56

Deferred Tax

0.02

5.55

4.73

-7.45

3.51

Reported Profit After Tax

205.01

262.87

229.88

252.5

182.33

Minority Interest After NP

0

0

0

0

0

Net Profit after Minority Interest

205.01

262.87

229.88

252.5

182.33

Extra-ordinary Items

0

0

0

3.34

0

Adjusted Profit After Extra-ordinary item

205.01

262.87

229.88

249.16

182.33

EPS (Unit Curr.)

12.1

15.52

13.57

14.67

10.76

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

240

120

0

Equity

169.41

169.41

169.41

169.41

169.41

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

36.62

38.37

34.44

35.7

32.67

PBDTM(%)

36.57

38.31

34.43

35.68

32.62

PATM(%)

25.46

26.97

24.21

24.98

22.38